Syngene International Q2 FY27 Financial Results and Operational Highlights
Syngene International Ltd 路 Investor Presentation 路 28 Oct 2026, 3:02 am
Syngene International Q2 FY27 Financial Results and Operational Highlights Syngene International reported Q2 FY27 revenue from operations of Rs 833 Cr, rising 13% QoQ but declining 9% YoY. Operating EBITDA margin stood at 18% (ex-forex hedge loss: mid-20s), while PAT before exceptional items was Rs 38 Cr, down 44% YoY. Reported PAT after exceptional items stood at Rs 32 Cr. For H1 FY27, revenue reached Rs 1,569 Cr, down 12% YoY. Operationally, Syngene signed its first manufacturing deal for the Bayview facility, secured new biologics supply contracts, and commissioned a Bengaluru Clinical Translational Sciences laboratory.
Original exchange filing (PDF)
More announcements from Syngene International Ltd
- Intimation of Schedule of Meetings with Analyst/Institutional Investor(s) 路 16 Nov 2026
- Intimation of Schedule of Meeting with Analyst/Institutional Investor(s) 路 13 Nov 2026
- Intimation of Earnings Conference call transcript for Q2 FY2027 路 02 Nov 2026
- Intimation of audio recording for Q2 FY27 post-earnings call 路 29 Oct 2026
- Press Release 路 28 Oct 2026
- Change in Management 路 28 Oct 2026
- Results- Financial Results for September 30, 2026. 路 28 Oct 2026
- Outcome of Board Meeting 路 28 Oct 2026
